Alto Neuroscience COO sells 75,000 shares in November
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alto Neuroscience, Inc. Chief Operating Officer Michael Conick Hanley Jr. exercised options for 75,000 shares at $2.35 per share from November 16 through November 18, 2026, and sold 75,000 shares over those dates. The transactions were made under a Rule 10b5-1 trading plan adopted August 14, 2026. Reported weighted-average sale prices were $27.4630, $28.4265, and $29.0863 on November 16, $26.8160 on November 17, and $26.48 on November 18.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (Right to Buy) F1, F5 | 2,896 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,896 | $2.35 | $7K |
| Sale | Common Stock F1 | 2,896 | $26.48 | $77K |
| Exercise | Employee Stock Option (Right to Buy) F1, F5 | 2,104 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 2,104 | $2.35 | $5K |
| Sale | Common Stock F1 | 2,104 | $26.816 | $56K |
| Exercise | Employee Stock Option (Right to Buy) F1, F5 | 17,729 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (Right to Buy) F1, F6 | 44,271 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (Right to Buy) F1, F7 | 8,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 17,729 | $2.35 | $42K |
| Exercise | Common Stock F1 | 44,271 | $2.35 | $104K |
| Exercise | Common Stock F1 | 8,000 | $2.35 | $19K |
| Sale | Common Stock F1, F2 | 56,410 | $27.463 | $1.55M |
| Sale | Common Stock F1, F3 | 10,895 | $28.4265 | $310K |
| Sale | Common Stock F1, F4 | 2,695 | $29.0863 | $78K |
Footnotes (7)
- F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 14, 2026.
- F2. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $26.95 to $27.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $27.95 to $28.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $28.95 to $29.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F5. 25% of the shares underlying the option vested on May 20, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
- F6. 25% of the shares underlying the option vested on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
- F7. The shares subject to the option are fully vested and exercisable.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.